We've found
10,036 Brain Cancer
clinical trials
Oncology Clinical Trial
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of the Effect IL 7/ NT-I7 on CD4 Counts in Patients With High Grade Gliomas
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of the Effect IL 7/ NT-I7 on CD4 Counts in Patients With High Grade Gliomas
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Brain Cancer Clinical Trial
Pilot Trial of Dose-Volume Constraints for Reirradiation of Recurrent Brain Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Neuroendocrine Tumors Clinical Trial
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Status: Enrolling,
Phase
Updated: 4/5/2018
Click here to add this to my saved trials
Neuroendocrine Tumors Clinical Trial
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Status: Enrolling,
Phase
Updated: 4/5/2018
Click here to add this to my saved trials
Neuroendocrine Tumors Clinical Trial
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Status: Enrolling,
Phase
Updated: 4/5/2018
Click here to add this to my saved trials
Neuroendocrine Tumors Clinical Trial
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Status: Enrolling,
Phase
Updated: 4/5/2018
Click here to add this to my saved trials
Neuroendocrine Tumors Clinical Trial
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Status: Enrolling,
Phase
Updated: 4/5/2018
Click here to add this to my saved trials
Neuroendocrine Tumors Clinical Trial
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Status: Enrolling,
Phase
Updated: 4/5/2018
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Neuroblastoma Maintenance Therapy Trial
Status: Enrolling,
Phase
II
Updated: 2/13/2018
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Neuroblastoma Maintenance Therapy Trial
Status: Enrolling,
Phase
II
Updated: 2/13/2018
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Neuroblastoma Maintenance Therapy Trial
Status: Enrolling,
Phase
II
Updated: 2/13/2018
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Neuroblastoma Maintenance Therapy Trial
Status: Enrolling,
Phase
II
Updated: 2/13/2018
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Neuroblastoma Maintenance Therapy Trial
Status: Enrolling,
Phase
II
Updated: 2/13/2018
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Neuroblastoma Maintenance Therapy Trial
Status: Enrolling,
Phase
II
Updated: 2/13/2018
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Neuroblastoma Maintenance Therapy Trial
Status: Enrolling,
Phase
II
Updated: 2/13/2018
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Neuroblastoma Maintenance Therapy Trial
Status: Enrolling,
Phase
II
Updated: 2/13/2018
Click here to add this to my saved trials
Glioblastoma Clinical Trial
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Status: Enrolling,
Phase
II
Updated: 10/20/2017
Click here to add this to my saved trials
Oncology Clinical Trial
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
High Grade Glioma, Glioblastoma Clinical Trial
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis
Status: Enrolling,
Phase
Updated: 12/12/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Trial of PT2977 Tablets In Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Glioblastoma Clinical Trial
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Glioblastoma Clinical Trial
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Glioblastoma Clinical Trial
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg
Status: Enrolling,
Phase
II
Updated: 7/28/2016
Click here to add this to my saved trials
Patients With Suspected Malignancies of the Pituitary Gland Clinical Trial
A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma
Status: Enrolling,
Phase
I
Updated: 12/6/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
We've found
10,036 Brain Cancer
clinical trials
Oncology Clinical Trial
Updated: 2/2/2016
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/2/2016
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/2/2016
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/2/2016
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/2/2016
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/2/2016
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/2/2016
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/2/2016
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/2/2016
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/2/2016
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/2/2016
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/2/2016
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/2/2016
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/2/2016
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/2/2016
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/2/2016
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/2/2016
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/2/2016
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 2/2/2016
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Status: Enrolling,
Phase
II
Updated: 2/2/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Study of the Effect IL 7/ NT-I7 on CD4 Counts in Patients With High Grade Gliomas
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Study of the Effect IL 7/ NT-I7 on CD4 Counts in Patients With High Grade Gliomas
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Brain Cancer Clinical Trial
Updated: 12/31/1969
Pilot Trial of Dose-Volume Constraints for Reirradiation of Recurrent Brain Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Neuroendocrine Tumors Clinical Trial
Updated: 4/5/2018
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Status: Enrolling,
Phase
Updated: 4/5/2018
Click here to add this to my saved trials
Neuroendocrine Tumors Clinical Trial
Updated: 4/5/2018
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Status: Enrolling,
Phase
Updated: 4/5/2018
Click here to add this to my saved trials
Neuroendocrine Tumors Clinical Trial
Updated: 4/5/2018
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Status: Enrolling,
Phase
Updated: 4/5/2018
Click here to add this to my saved trials
Neuroendocrine Tumors Clinical Trial
Updated: 4/5/2018
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Status: Enrolling,
Phase
Updated: 4/5/2018
Click here to add this to my saved trials
Neuroendocrine Tumors Clinical Trial
Updated: 4/5/2018
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Status: Enrolling,
Phase
Updated: 4/5/2018
Click here to add this to my saved trials
Neuroendocrine Tumors Clinical Trial
Updated: 4/5/2018
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Status: Enrolling,
Phase
Updated: 4/5/2018
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Updated: 2/13/2018
Neuroblastoma Maintenance Therapy Trial
Status: Enrolling,
Phase
II
Updated: 2/13/2018
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Updated: 2/13/2018
Neuroblastoma Maintenance Therapy Trial
Status: Enrolling,
Phase
II
Updated: 2/13/2018
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Updated: 2/13/2018
Neuroblastoma Maintenance Therapy Trial
Status: Enrolling,
Phase
II
Updated: 2/13/2018
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Updated: 2/13/2018
Neuroblastoma Maintenance Therapy Trial
Status: Enrolling,
Phase
II
Updated: 2/13/2018
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Updated: 2/13/2018
Neuroblastoma Maintenance Therapy Trial
Status: Enrolling,
Phase
II
Updated: 2/13/2018
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Updated: 2/13/2018
Neuroblastoma Maintenance Therapy Trial
Status: Enrolling,
Phase
II
Updated: 2/13/2018
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Updated: 2/13/2018
Neuroblastoma Maintenance Therapy Trial
Status: Enrolling,
Phase
II
Updated: 2/13/2018
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Updated: 2/13/2018
Neuroblastoma Maintenance Therapy Trial
Status: Enrolling,
Phase
II
Updated: 2/13/2018
Click here to add this to my saved trials
Glioblastoma Clinical Trial
Updated: 10/20/2017
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Status: Enrolling,
Phase
II
Updated: 10/20/2017
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
High Grade Glioma, Glioblastoma Clinical Trial
Updated: 12/31/1969
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/12/2016
Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis
Status: Enrolling,
Phase
Updated: 12/12/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Trial of PT2977 Tablets In Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Glioblastoma Clinical Trial
Updated: 12/31/1969
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Glioblastoma Clinical Trial
Updated: 12/31/1969
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Glioblastoma Clinical Trial
Updated: 12/31/1969
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 7/28/2016
Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg
Status: Enrolling,
Phase
II
Updated: 7/28/2016
Click here to add this to my saved trials
Patients With Suspected Malignancies of the Pituitary Gland Clinical Trial
Updated: 12/6/2016
A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma
Status: Enrolling,
Phase
I
Updated: 12/6/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials